secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-07-07T23:59:59+00:00
Accession:  0001171843-25-004324
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst appoints Babar Ghias as CFO and Head of Corporate Development
----------------------------------------------------------------------

- Babar Ghias named CFO, effective July 7, 2025; also serves as Principal Accounting Officer.
- Annual base salary of $560,000; target bonus 70% of salary; one-time cash bonus of $160,000.
- Inducement grants: 147,000 RSUs and options to purchase 305,000 shares, vesting over 4 years.
- Ghias joins from AvenCell Therapeutics; previously EVP at Paragon Biosciences and CFO at Marathon Pharmaceuticals.
- CEO Stonehouse cites Ghias' deal-making and operational experience for growth and capital deployment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184325004324/0001171843-25-004324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184325004324/f8k_070725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer